Fort Washington, PA, September 29, 2010 --Vitae Pharmaceuticals announced today that the
inaugural, Pennsylvania-area LifeSciences Awards program has recognized President and CEO
Jeffrey Hatfield as a Life Sciences CEO of the Year. Vitae is a clinical-stage biopharmaceutical
company building a portfolio of novel, small molecule, best-in-class compounds that address
large markets with significant unmet medical needs, including chronic kidney disease, diabetes,
Alzheimer's disease and atherosclerosis.
An independent panel of judges from leading universities in the state selected the winners of the
Life Sciences Awards, which serve to recognize the region’s medical miracle makers for their
innovative approaches to improving the delivery of health care. The Life Sciences Awards are
presented by The Philadelphia Business Journal and have been launched in sponsorship with the
University of the Sciences and partners Pennsylvania Bio and Safeguard Scientifics.
“I am honored to be among such as a select group of CEOs recognized by the Life Sciences
Awards program,” stated Mr. Hatfield. “The Pennsylvania region is distinguished as a leading
center for innovation, and Vitae is pleased to be a part of this thriving life sciences community.”
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company building a portfolio of
novel, small molecule, best-in-class compounds that address large markets, including chronic
kidney disease, diabetes, Alzheimer’s disease and atherosclerosis. Vitae’s lead compound, VTP-27999, is a wholly owned, novel, potent and selective renin inhibitor offering the potential for
superior renal protection in patients suffering from chronic kidney disease. The compound is
advancing through Phase I clinical trials and results will be presented by early 2011.
Vitae is an expert in structure-based drug discovery and combines a proprietary technical
platform with the experience and insight of world class scientists to advance best-in-class
compounds for high value, hard-to-drug targets. Vitae’s proprietary, discovery platform has clear
advantages in creating and analyzing novel drug candidates that meet pre-defined
physicochemical characteristics. The accuracy and speed of this system has enabled Vitae to
solve challenging targets in multiple therapeutic areas -- discovering and advancing attractive
compounds in a rapid and highly capital efficient manner. Vitae Pharmaceuticals is financed by
leading corporate and venture capital investors; its last venture round was in 2004. Vitae’s 45
scientists are located in Fort Washington, Pennsylvania. For additional information, please visit
the company’s website, www.vitaepharma.com.
Burns McClellan on behalf of Vitae
Justin Jackson, MichelleSzwarcberg (media),